Meningiomas are common central nervous system tumors; however, the molecular mechanisms underlying their pathogenesis are largely undefined. Previous work has implicated Protein 4.1B as an important tumor suppressor involved in the development of these neoplasms. In this report, we demonstrate that the U2 domain is necessary and sufficient for the ability of Protein 4.1B to function as a meningioma growth suppressor. Using a series of truncation and deletion constructs of DAL-1 (a fragment of Protein 4.1B that retains all the growth suppressive properties), we narrowed the domain required for 4.1B growth suppression to a fragment containing a portion of the FERM domain and the U2 domain using clonogenic assays on meningioma cells. Deletion of the U2 domain in the context of the full-length DAL-1 molecule eliminated growth suppressor function, as measured by thymidine incorporation and caspase-3 activation. Moreover, targeting the U2 domain to the plasma membrane using a membrane localization signal (MLS) reduced cell proliferation, similar to wild-type DAL-1. Collectively, the data suggest that the U2 domain, when properly targeted to the plasma membrane, contains all the residues necessary for mediating Protein 4.1B growth suppression.
Introduction
Meningiomas are one of the most common nervous system tumors, yet little is known about the specific genetic alterations associated with meningioma formation or progression. To date, the most widely studied genetic change associated with meningioma tumorigenesis is chromosome 22q loss of heterozygosity (LOH) with inactivation of the NF2 gene (Ruttledge et al., 1994; Gutmann et al., 1997; Huynh et al., 1997; Leone et al., 1999; Ueki et al., 1999) . This mechanism of tumor suppressor gene inactivation, consisting of chromosomal 22q deletion combined with a subtle mutation of the remaining allele, is implicated in approximately half of sporadic meningiomas. Other genetic alterations associated with meningioma progression include p16 (CDKN2A) inactivation and PS6K (17q23) amplification (Tse et al., 1998; Bostrom et al., 2001; Cai et al., 2001 , Surace et al., 2004 as well as chromosome 1p, 3p, 6q, 10q, and 14q deletions (Simon et al., 1995; Perry et al., 1996; Menon et al., 1997; Weber et al., 1997; Leone et al., 1999) . In addition, chromosomal gains involving 1q, 9q, 12q, 15q, 17q, and 20q have also been reported (Simon et al., 1995; Weber et al., 1997) . To date, the specific genes that localize to these chromosomal regions of deletion or amplification have not been identified.
The NF2 gene encodes a 595 amino-acid cytoplasmic protein (merlin or schwannomin) structurally related to the Protein 4.1 family of molecules. As a negative growth regulator, merlin suppresses cell proliferation when overexpressed in meningioma cell lines or NF2-deficient meningioma primary cultures (Ikeda et al., 1999) . Moreover, targeted leptomeningeal inactivation of the Nf2 gene in mice in vivo is associated with meningeal hyperplasia and subsequent meningioma formation (Kalamarides et al., 2002) . Collectively, these data suggest that merlin is a critical growth regulator for leptomeningeal cells and that NF2 inactivation occurs early in the development of sporadic meningiomas.
Studies from our laboratory have implicated another Protein 4.1 tumor suppressor, Protein 4.1B, in the molecular pathogenesis of meningioma Gutmann et al., 2001) . DAL-1 (Differentially expressed in Adenocarcinoma of the Lung-1) was originally discovered by Differential Display reverse transcription (RT)-PCR as a 750 nucleotide gene fragment whose expression was absent in several nonsmall-cell lung carcinomas (NSCLC) when compared to matched normal tissue (Tran et al., 1999) . In addition, the reintroduction of DAL-1 into nonexpressing NSCLC cell lines resulted in a suppression of growth (Tran et al., 1999) . Subsequent analysis revealed that DAL-1 represented a fragment of the Protein 4.1B gene ) located on chromosome 18p11.3 (Peters et al., 1998) . Protein 4.1B is composed of several domains including three unique regions (U1, U2, and U3), an N-terminal FERM (4.1, ezrin, radixin, moesin) domain, a spectrin-actin binding region (SABD), and a C-terminal domain (CTD) .
In previous experiments, we have shown that the minimal domain required for Protein 4.1B growth suppression in meningioma cells is contained between residues M 110 and S
851
, corresponding to the DAL-1 fragment . Similar to merlin, reexpression of the DAL-1 fragment suppressed cell proliferation in meningioma cells , suggesting that Protein 4.1B may play a specific role in the control of meningeal cell proliferation. While it is not known how Protein 4.1B functions to suppress cell growth, overexpression of DAL-1 results in increased programmed cell death (apoptosis) in breast cancer cell lines (Charboneau et al., 2002) .
To define the critical domains of Protein 4.1B that contain the elements necessary for growth suppression, we examined a series of Protein 4.1B deletion mutants and demonstrate that the minimal growth suppressor domain contains residues M 277 through T 724 (latter half of the FERM domain and the entire U2 domain). We further show that deletion of the U2 domain in the context of the full-length DAL-1 protein abrogates DAL-1 growth suppression. Previous studies from our laboratory and others have shown that DAL-1 binds to two transmembrane glycoproteins (CD44 and Tumor Suppressor in Lung Cancer 1, TSLC1), suggesting that the FERM domain might localize Protein 4.1B to the plasma membrane to initiate growth suppressor signaling. Since the FERM domain fragment contains the amino-acid residues required for membrane targeting and binding to transmembrane glycoproteins, we targeted the U2 domain to the plasma membrane and demonstrated that U2 membrane localization is sufficient for meningioma growth suppression. Collectively, the data suggest that the U2 domain, when properly targeted to the plasma membrane, is both necessary and sufficient to account for the growth suppressor properties of Protein 4.1B.
Results
Although DAL-1 is not a naturally occurring protein, previous studies in our laboratory have demonstrated that this fragment of Protein 4.1B contains the aminoacid residues necessary for the growth suppressor function of Protein 4.1B in meningioma cells . In this regard, DAL-1 has also been shown to interact with all known Protein 4.1B-binding partners Yu et al., 2002 , Robb et al., 2003 and has the same localization pattern (plasma membrane) as Protein 4.1B (Tran et al., 1999; Parra et al., 2000; Yageta et al., 2002) . Therefore, we generated a series of deletion constructs in the context of DAL-1 to define the minimal region that mediates the growth suppressive function of Protein 4.1B (Figures 1a and  2a) -A 464 (FERM domain) had no effect on colony number, indicating that the minimal growth suppression domain requires both the presence of the FERM and U2 domains. It is interesting to note that M 110 -P 488 (the FERM and aminoterminal U2 domains) also had no effect on colony number. Collectively, this suggests that the FERM domain and, at a minimum, the carboxyl-terminal of the U2 domain is necessary for colony suppression, although a construct containing the U2 domain alone does not reduce colony number (not shown). Identical results were also obtained using another human meningioma cell line, IOMM-Lee ( Figure 1d ).
To further narrow the potential minimal Protein 4.1B growth suppressor domain, we generated additional FERM domain mutants with sequential N-terminal FERM domain deletions (Figure 2a) . Overexpression of these additional DAL-1 mutants did not suppress colony formation (Figure 2c ), demonstrating that the minimal growth suppression domain is contained within a region encompassing amino-acid residues 277 and 724. This region corresponds to the carboxyl-terminal half of the FERM domain and the U2 domain of Protein 4.1B. Studies have shown that the FERM domain of Protein 4.1 proteins bind to CD44 (Nunomura et al., 1997; Legg and Isacke, 1998; Yonemura et al., 1998) (Figure 2d ). Based on these findings, we hypothesize that the ability of 4.1B to suppress meningioma cell growth requires proper localization of the U2 domain to the cell membrane.
Since the FERM domain is highly homologous among Protein 4.1 molecules, we reasoned that the residues within the U2 domain are responsible for Protein 4.1B growth suppression and that the FERM domain is primarily required for proper membrane localization. To test this hypothesis, we generated a DAL-1 mutant, designated DU2, identical to wild-type DAL-1 except for a deletion of the U2 domain (Figure 3a) . To ensure that the interaction of the DU2 DAL-1 mutant did not disrupt binding to other known Protein 4.1B/DAL-1 interactors, we analysed DU2 mutant and wild-type DAL-1 binding to CD44, bIIspectrin, and 14-3-3. GST affinity experiments demonstrated that mutant DU2 interacts with bII-spectrin and 14-3-3, similar to wild-type DAL-1 (Figure 3b ). In addition, in vivo interaction studies demonstrated that both wild-type DAL-1 and mutant DU2 interact with CD44 ( Figure 3c ). Collectively, these data indicate that the DU2 mutation is capable of binding to known interactors of DAL-1, suggesting that deletion of the U2 domain does not globally disrupt DAL-1 protein structure.
To (containing only the U2, SABD, and U3 domains), constructs containing the FERM domain (DAL-1 and DU2) were expressed in the membrane fraction (Figure 4b ).
To confirm that the DAL-1 and DU2 proteins both localized to the plasma membrane, additional subcellular fractionation experiments were performed using density gradient centrifugation. Consistent with the (Tran et al., 1999; Parra et al., 2000) , both the DAL-1 and DAL-1 DU2 mutant proteins are found in the lowest density fractions containing plasma membrane components (Yang et al., 1997) (Figure 4c ). Anti-membrin immunoblotting was used to visualize fractions containing Golgi membranes (Lowe et al., 1997) , which fractionate at a higher density than plasma membrane proteins (Yang et al., 1997) . In contrast to DAL-1, the DAL-1 E 465 -S 851 was found in the higher density fractions.
To determine the effect of U2 deletion on DAL-1 growth suppression, IOMM-Lee cell proliferation was determined by thymidine incorporation. IOMM-Lee cells expressing wild-type DAL-1 exhibited a 40-60% reduction in thymidine incorporation, compared to vector controls ( Figure 5a ). In contrast, stable expression of E 465 -S 851 or the DU2 mutant had no effect on IOMM-Lee cell proliferation. Although the mechanism by which DAL-1 regulates cell growth is currently unknown, one mechanism by which DAL-1 may reduce meningioma cell growth is through increased programmed cell death (apoptosis). To investigate this possibility, we assessed the apoptotic indices of these IOMM-Lee cell lines by immunofluorescence using antibodies that recognize cleaved (activated) caspase-3. Compared to vector alone, IOMM-Lee cells expressing wild-type DAL-1 exhibited a five-fold increase in the number of caspase 3-positive apoptotic cells (Figure 5b ). Consistent with the thymidine proliferation results, expression of E 465 -S 851 or the DU2 mutant in IOMMLee cells had no effect on the apoptotic index.
To gain potential insights into the mechanism(s) underlying DAL-1 growth suppression in IOMM-Lee meningioma cells, we employed Affymetrix-based microarray gene expression profiling on two independent DAL-1-expressing (lines #4 and #10) and two independent vectors-expressing (lines #3 and #4) IOMM-Lee clones. Expression of three transcripts in the programmed cell death pathway was increased in the two DAL-1-expressing IOMM-Lee cell lines relative to vector controls: caspase-1 (3.6-fold), toll-like receptor-4 (TLR4; 5.5-fold), and grb2-associated binding protein-1 (gab1; 2.6-fold). Each was validated by quantitative RT-PCR ( Figure 6a ). We next analysed the expression of caspase-1 on the protein level in IOMM-Lee cells stably expressing vector, DAL-1, or DAL-1 missing the U2 domain (DU2 mutant), and found upregulation of caspase-1 expression only in the DAL-1-expressing cells capable of inducing programmed cell death in (Figure 6b ). In addition, given the role of the Jun-kinase (JNK) pathway in triggering programmed cell death (Kanda and Miura, 2004) , we examined JNK activation using a phospho-specific antibody, and found that only the DAL-1-expressing IOMM-Lee cells exhibited increased JNK activation (Figure 6b ). Collectively, these results suggest that DAL-1 activates programmed cell death (apoptosis) by upregulating the expression and activation of key members of the apoptotic pathway in human meningioma cells.
To further investigate the role of the U2 domain in Protein 4.1B growth suppression, we designed a construct to target U2 to the cell membrane, designated membrane localization signal (MLS)-U2 (Figure 7a ). The MLS chosen for these studies has been previously employed to successfully target proteins to the plasma membrane (Toby et al., 1998) . As a negative control, an additional construct, MLS-SU3, was also designed to target the SAB and U3 domains of Protein 4.1B to the membrane ( Figure 7a ). As the small protein size of these constructs precluded immunoblotting and the establishment of stable cell lines, we utilized fluorescence immunocytochemistry to ensure proper localization and clonogenic assays to evaluate effects on meningioma growth suppression. RT4 schwannoma cells were transfected with equimolar amounts of pcDNA3, pcDNA3.myc.DAL-1, pcDNA3.MLS-U2, or pcDNA3. MLS-SU3 followed by fluorescence immunocytochemistry using a DAL-1-specific antibody (Figure 7b ). Overexpression of either MLS-U2 or MLS-SU3 resulted in a subcellular localization similar to that of DAL-1, with both cytoplasmic and membrane staining observed. Wild-type DAL-1 and DU2 mutant binding to 14-3-3 and bII-spectrin were examined by GST affinity interactions as described in the Materials and methods section. The bound and supernatant fractions are shown for each representative interaction. Both wild-type DAL-1 and the DU2 mutant exhibited significant binding to 14-3-3 and bII-spectrin. No significant binding to GST alone was observed. (c) Wild-type DAL-1 and the DU2 mutant interact with CD44 in vivo. RT4 cells were transfected with 3 mg of pcDNA3.myc.DAL-1 or pcDNA3.myc. DU2. Cells were lysed and DAL-1-associated proteins were isolated using myc beads. For each sample, the bound fraction and total cell lysate are shown. Bound proteins were identified by Western blot analysis using anti-CD44 antibodies Crude membrane fractions isolated from these IOMM-Lee cell lines were analysed by Western immunoblotting indicating that both full-length DAL-1 and DAL-1 DU2 localize to the membrane fraction, contrary to the E 465 -S 851 mutant. (c) Density gradient subcellular fractionation method further confirms that DAL-1 and DAL-1 DU2 localize to plasma membrane fractions. Antimembrin immunoblotting was used to visualize fractions containing Golgi membranes
The effect of targeting the U2 domain to the plasma membrane on growth suppression in meningioma cells was evaluated by clonogenic assay. We found that overexpression of MLS-U2 resulted in a 50% reduction in IOMM-Lee colonies compared to vector, similar to that observed with DAL-1 overexpression (Figure 7c ). In contrast, overexpression of MLS-SU3 had no effect on colony number (Figure 7d) , demonstrating the specific effect of the U2 domain on meningioma growth regulation. To ensure that the growth suppressive effect of MLS-U2 was not due to a cytotoxic effect or differences in transfection efficiency, we repeated the colony suppression assays in rat RT4 schwannoma cells, whose growth is not reduced by DAL-1 overexpression. In these experiments, overexpression of MLS-U2 had no effect on colony number (Figure 7e) . Collectively, these results suggest that the U2 domain, when properly targeted to the cell membrane, is both necessary and sufficient to account for Protein 4.1B meningioma growth suppression.
Discussion
One of the main functions of Protein 4.1 family members is the structural stabilization of the cell membrane (Tchernia et al., 1981) ; however, recent work has demonstrated that certain members of the Protein 4.1 family have additional roles as tumor suppressors. In this regard, Protein 4.1R and Protein 4.1B have been reported to function as negative growth regulators in the pathogenesis of a diverse number of human cancers (Tran et al., 1999; Huang et al., 2001; Charboneau et al., 2002) , including meningiomas (Gutmann et al., 1997 Perry et al., 2000; Robb et al., 2003) . The present study was undertaken to define the critical domain of Protein 4.1B necessary for meningioma growth suppression as a first step towards elucidating the molecular mechanism underlying Protein 4.1B function. In this report, we demonstrate that the minimal growth suppressor domain of Protein 4.1B resides within amino acids M 277 -T 724 , corresponding to residues within the carboxyl half of the FERM domain and the entire U2 domain. Further N-terminal deletion of FERM residues abolishes both the ability of these constructs to suppress meningioma cell growth as well as the ability to localize appropriately to the plasma membrane. Although there are differences in the subcellular localization of various members of the Protein 4.1 family, localization to the cell membrane is a common feature (reviewed in Sun et al., 2002) . A primary determinant for this localization appears to be the conserved N-terminal FERM domain and its interaction with membrane-bound molecular partners. Disruption of the FERM domain prevents proper membrane localization of Protein 4.1 family members and, in the case of merlin, impairs tumor suppressor activity (Deguen et al., 1998; Brault et al., 2001; Dard et al., 2004) . Similar to the R 328 -S 851 DAL-1 mutant in this report, mutant merlin proteins with deletions within the N-terminal domain were unable to properly localize or function as growth regulators (Deguen et al., 1998; Brault et al., 2001) . Merlin and Protein 4.1B have both been shown to bind to CD44 (Morrison et al., 2001; Robb et al., 2003) , and in the case of merlin, the Figure 7 The U2 domain of Protein 4.1B is capable of growth suppression when targeted to the membrane. (a) Schematic of the domains present in full-length DAL-1 and additional constructs generated to determine the effect of targeting the U2 domain to the membrane. MLS, membrane localization signal. (b) RT4 cells were transfected with equimolar amounts of constructs and analysed by fluorescence immunocytochemistry. Photographs were taken at Â 400 magnification. The upper panels demonstrate specific protein localization; middle panels depict specific staining merged with the phalloidin-BODIPY to highlight the actin cytoskeleton; lower panels show bis-benzimide nuclear staining. (c) Using a clonogenic assay, overexpression of MLS-U2 in IOMM-Lee cells resulted in growth suppression similar to that observed with DAL-1 overexpression. (d) Growth suppression was not observed with overexpression of MLS-SU3. (e) Overexpression of MLS-U2 had no effect on RT4 schwannoma cell colony number. NF2 (merlin) was included as a positive control Role of the U2 domain in protein 4.1B growth suppression VA Robb et al transduction of NF2 growth inhibition signals from the extracellular matrix is dependent on this interaction (Morrison et al., 2001) . The recent identification of another CD44-like protein, TSLC1, which associates with Protein 4.1B (Yageta et al., 2002) , suggests that additional transmembrane proteins may be involved in Protein 4.1B growth regulation. While the specific residues critical for mediating these interactions have not been identified, the regions of 4.1B important for CD44/TSLC1 binding are contained within the fragments used in this study that mediate plasma membrane localization (Robb VA, Surace EI and Gutmann DH, unpublished observations). Taken together, these observations suggest that the N-terminal FERM domain may be the main determinant that provides the proper membrane localization for 4.1B growth regulation. Studies are presently underway to determine how CD44 and TSLC1 binding to Protein 4.1B activate specific downstream signaling pathways important for meningioma cell proliferation and apoptosis. The importance of the FERM domain for appropriate Protein 4.1 localization and function coupled with the observation that the minimal growth suppression domain of Protein 4.1B includes FERM residues and the entire U2 domain suggested to us that the residues within the U2 domain alone may be entirely responsible for Protein 4.1B growth suppression. In this model, the FERM domain is hypothesized to function primarily to target the U2 domain of 4.1B to the plasma membrane where it can productively interact with upstream regulatory and downstream effector molecules. Consistent with this hypothesis, deletion of the U2 domain had no effect on DAL-1 subcellular localization or the ability of DAL-1 to bind to known interacting proteins, but completely abolished the ability of DAL-1 to function as a meningioma tumor suppressor. Moreover, targeting the U2 domain to the membrane using a MLS was sufficient to induce meningioma growth suppression, similar to that seen with full-length DAL-1. Collectively, these results suggest that the U2 domain, when properly targeted to the cell membrane, is sufficient for Protein 4.1B meningioma growth suppression.
It should be appreciated that the membrane localization imparted by the MLS targeting sequence is artificial and nonphysiologic, and only serves to bring the DAL-1 growth regulatory domain to the plasma membrane where it can interact with its downstream effector proteins and initiate the proper signaling pathways necessary for Protein 4.1B growth suppression. The ability of the MLS-U2 construct to suppress meningioma cell growth should not be interpreted as excluding the critical roles of CD44 or TSLC1 in modulating 4.1B growth regulation. We suggest that CD44/TSLC1 provides the correct contextual and physiologic cues that engage Protein 4.1B localization and activity. In previous studies, the ability of merlin to function as a negative growth regulator in schwannoma cells is abrogated by interfering with endogenous CD44 binding, thus inhibiting merlin targeting to the plasma membrane (Morrison et al., 2001) . Similarly, we envision that CD44/TSLC1 are activated by specific extracellular signals (e.g. cell contact) and recruit Protein 4.1B to the plasma membrane to interact with its appropriate signaling partners. Future studies are in progress to define the cellular contexts that result in Protein 4.1B localization to the cell membrane and initiate growth suppression.
Although this report provides strong evidence that the proper localization of the U2 domain is sufficient for Protein 4.1B growth suppression, the mechanisms underlying Protein 4.1B growth suppression are still not clear. To provide insight into possible mechanism(s) mediating Protein 4.1B growth suppression, efforts have focused on characterizing potential interacting proteins that might mediate the Protein 4.1B growth inhibitory signal. Protein 4.1B interacts with CD44 (Robb et al., 2003) , bII-spectrin Gimm et al., 2002 ), 14-3-3 (Yu et al., 2002 , Protein Arginine NMethyltransferase 3 (PRMT3, Singh et al., 2004) , and the membrane proteins Caspr/paranodin and Caspr2 (Denisenko-Nehrbass et al., 2003) . Currently, there are no known interactors that specifically bind within the U2 domain of Protein 4.1B / DAL-1. Using the U2 domain as bait, yeast two-hybrid analysis of a fetal brain library representing more than 1.5 million cotransfectants led to the isolation of almost 100 potential clones, but none were confirmed as true interactors (HartMahon EK, Robb VA and Gutmann DH, unpublished data). Moreover, a BLAST search of the U2 domain sequence did not reveal significant homology to other known proteins, including other Protein 4.1 molecules, underscoring the uniqueness of the U2 domain, but at the same time, did not provide any structural clues to Protein 4.1B function as a negative growth regulator. Studies are currently underway to identify Protein 4.1B interactors that associate with the U2 domain and mediate cell cycle regulation and apoptosis.
These studies also demonstrate that Protein 4.1B/ DAL-1 functions as a meningioma tumor suppressor, at least in part, through the induction of cell death, as has been previously shown for breast cancer cells (Charboneau et al., 2002) . Similarly, overexpression of merlin has also been demonstrated to induce programmed cell death in human schwannoma cells (Schulze et al., 2002) and in NIH3T3 cells, the latter of which was mediated by stabilizing p53 expression (Kim et al., 2004) . Studies on another member of the Protein 4.1 family, ezrin, have shown that the association of CD95 (Fas/APO-1) with ezrin and the subsequent linkage of this complex to the actin cytoskeleton are essential for CD95-mediated apoptosis in CD4 þ T lymphocytes (Lozupone et al., 2004) . Interestingly, an activating point mutant of ezrin induced apoptosis in epithelial cells via activation of the PI 3-kinase/Akt pathway (Gautreau et al., 1999) . We examined this important cell death pathway, but did not observe activation of the PI 3-kinase/Akt pathway or changes in the expression or activation of the antiapoptotic protein bcl2 in response to DAL-1 expression in IOMM-Lee meningioma cells (Robb VA and Gutmann DH, unpublished observations) . These preliminary results suggest that Protein 4.1B may utilize other signaling pathways to activate programmed cell death. In this regard, our gene expression profiling data demonstrates that the expression of several apoptotic pathway genes is regulated by DAL-1 in meningioma cells. We show that caspase-1, TLR4, and gab1 are upregulated upon DAL-1 expression in IOMM-Lee meningioma cells. TLR4 activation in macrophages has been shown to result in increased caspase-1 activation and apoptosis through the activation of JNK, which is mediated by JNK interacting protein (JIP3) binding to TLR4 (Matsuguchi et al., 2003; Zhang et al., 2003; Mariathasan et al., 2004) . Similarly, gab1 functions as a key integrator of apoptosis, such that gab1 À/À mouse embryonic fibroblasts display reduced apoptotic cell death and impaired JNK activation (Holgado-Madruga and Wong, 2003; Sun et al., 2004) . Based on these observations, it is possible that Protein 4.1B results in programmed cell death by activating TLR4/gab1 signaling through JNK to initiate caspase-mediated apoptosis. Studies are in progress to determine the functional relationship between these programmed cell death genes, JNK activation, and Protein 4.1B growth suppression.
Although the precise signal transduction pathways that mediate Protein 4.1 growth suppression have not been fully defined, the sequence homologies and structural similarities between merlin and Protein 4.1B permit us to conceive a model whereby transmembrane receptors, such as CD44/TSLC1, link contextual growth signals from the extracellular environment to the nucleus via interactions with Protein 4.1B. In this model, CD44/TSLC1 binding to Protein 4.1B through residues in the FERM domain facilitates the localization of the U2 domain to the plasma membrane, and initiates specific signaling cascades that ultimately lead to apoptosis and reduced cell growth. The findings described in this report highlight the importance of membrane targeting to DAL-1 growth suppression and identify a critical region of the Protein 4.1B molecule that mediates meningioma growth regulation.
Materials and methods

Generation of constructs
The DAL-1 cDNA used in these experiments was of human origin as previously described (Tran et al., 1999) . DAL-1 fragments were generated by PCR using the following primer pairs: Construct M 0 . PCR products containing a 5 0 -SpeI restriction site were initially cloned into pCR2.1 T/A cloning vector (Invitrogen Inc., Carlsbad, CA, USA) and sequenced in their entirety before subcloning into a pcDNA3.myc vector generated in our laboratory.
A MLS was used to target proteins to the membrane as has been described previously (Toby et al., 1998) . The MLS fragments were generated by PCR using the following primer pairs: MLS-U2: 5 0 -AAGCTTGCCATGGGGAGTAGCAA GAGCAAGGAGGTTGGTACTGGCCAG-3 0 and 5 0 -TCAC TCAGTGGCGGTGGTCTC-3 0 ; MLS-SU3: 5 0 -AAGCTTGC CATGGGGAGTAGCAAGAGCAAGGAGCTAGAAAAA ACTCAAG-3 0 and 5 0 -CTATCCACTGGACTCCGTCTTG-3 0 . PCR products containing a 5 0 -HindIII restriction site were initially cloned into pCR2.1 T/A cloning vector and sequenced in their entirety before subcloning into pcDNA3.
The DU2 construct was generated using the QuikChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA) according to the manufacturer's instructions and using the following primer pair: 5 0 -CTATGTCTGCTGCAGAG-GAGCTAGAAAAAAC-3 0 and 5 0 -GTTTTTTCTAGCTCC TCTGCAGCAGACATAG-3 0 . The construct was sequenced in its entirety to verify the mutation.
Western blotting
Protein expression was assessed by transient transfection of RT4 rat schwannoma cells. After 48 h, cells were eluted in 2 Â Laemmli sample buffer, loaded on 12% SDS-PAGE gels, and separated by electrophoresis. Proteins were transferred onto Immobilon membranes (Millipore, Bedford, MA, USA) for Western blotting using anti-myc (1 : 100; 9E10, Santa Cruz Biotechnologies, Santa Cruz, CA, USA) antibodies. Western blots were developed using horseradish peroxidase-conjugated secondary antibodies (1 : 2000; #7074, Cell Signaling Technology, Beverly, MA, USA) and ECL chemiluminescence (Amersham Biosciences, Piscataway, NJ, USA).
To investigate the role of apoptosis, lysates from IOMMLee cells stably expressing vector, DAL-1, or DAL-1 missing the U2 domain (DU2 mutant) were assayed using the following specific antibodies: anti-caspase 1 (1 : 1000; #06-503, Upstate, Charlottesville, VA, USA) and anti-phospho-JNK (1 : 1000; #9251, Cell Signaling Technology), and developed as above.
Clonogenic assays
Clonogenic assays used the well-characterized human meningioma cell lines, CH157-MN and IOMM-Lee (Lee, 1990) . Cells were transfected (at approximately 60% confluence) with equimolar amounts of DNA constructs. Quadruplicate 60 mm plates for each transfection were grown for 2 weeks in the presence of geneticin (Gibco BRL, Grand Island, NY, USA). The number of colonies was counted after Crystal violet staining (Sigma, St Louis, MO, USA), with the mean and standard deviation determined for each condition. This experiment was repeated at least three times with identical results. To assess the transfection efficiency in each transfection, IOMM-Lee cells were cotransfected with equimolar amounts of pCMS-EGFP (#6101-1, Clontech Laboratories, Inc., Palo Alto, CA, USA) and pcDNA3.myc, pcDNA3.myc. DAL-1, or pcDNA3.myc.DAL-1 DU2. Transfection efficiency was determined by counting the number of EGFP-expressing cells in each transfection by immunofluorescence microscopy. No significant differences in transfection efficiency were observed (data not shown). . Cells were selected in 500 mg/ml geneticin for 2 weeks before individual clones were selected. Protein expression was determined by Western blot using anti-myc antibodies. Two clones each were selected for further analysis.
Generation of stable cell lines
Thymidine incorporation assay
For thymidine incorporation experiments, 10 5 cells of each cell line were plated in six wells of a 24-well plate. After 24 h, the media was changed to serum-free DMEM and incubated at 371C for 24 h, then replaced with serum-free DMEM containing 1mCi/ml 3 H-thymidine (Amersham) for 4 h. Cells were washed twice with PBS and solubilized in 200 mM NaOH. Counts per minute (d.p.m.) were determined in a Liquid Scintillation Beta Analyzer (Packard Instruments Co., Meridan, CT, USA), with the mean and standard deviation determined for each cell line. This experiment was repeated at least three times with similar results.
Immunofluorescence immunocytochemistry
As IOMM-Lee cells have a low transfection efficiency, RT4 cells were transfected with 3 mg of DNA to examine subcellular protein expression. Comparison of IOMM-Lee and RT4 cells transfected with DAL-1 yielded similar patterns of subcellular localization (Robb et al., 2003) . After 48 h, cells were fixed with 4% paraformaldehyde, permeabilized with 0.2% Triton, washed, blocked with PBS containing 10% goat serum and 1% BSA, and incubated overnight with anti-Protein 4.1B (1 : 1000, 3A-1). Immunofluorescence detection was achieved using Alexa 568 anti-rabbit secondary antibody (1 : 500, Molecular Probes, Inc., Eugene, OR, USA). Cells were counterstained with BODIPY-Phalloidin (Molecular Probes) and bis-benzimide (Sigma) to identify the actin cytoskeleton and nucleus, respectively.
The apoptotic index of IOMM-Lee stable cell lines was assessed using antibodies that recognize cleaved caspase 3. For each line, 10 4 cells were plated in one well of a 24-well plate. After 24 h, the plate was fixed with 4% formaldehyde, washed, permeabilized with 0.25% Triton, washed, blocked with PBS containing 10% goat serum, and incubated overnight with anti-caspase 3 (1 : 500, Molecular Probes). Immunofluorescence detection was achieved using Alexa 568 anti-rabbit secondary antibody (1 : 500). Cells were counterstained with DAPI to identify the nucleus. For each experiment, approximately 200 nuclei per cell line were counted and the number of caspase 3-positive nuclei was recorded. This experiment was repeated four times and the mean and standard deviation was determined for each cell line.
Isolation of membrane fractions
IOMM-Lee cells were trypsinized and split into two aliquots. One aliquot was pelleted (total lysate). The second aliquot was resuspended in hypotonic lysis buffer (10 mM KCl, 10 mM Tris, pH 7.4, 1.5 mM MgCl 2 , 1 mM PMSF) plus protease inhibitors (leupeptin, DTT, benzamidine, aprotinin, and PMSF), incubated on ice for 15 min, and Dounce homogenized. Lysates were centrifuged at 4000 r.p.m. for 5 min and the supernatant was transferred to a new tube. The supernatant was centrifuged at 100 000 g for 40 min at 41C and the pellet containing the membrane fraction was saved. The pellets were lysed in NP40 lysis buffer and protein concentration was determined using the BCA kit. Electrophoresis and Western blotting was as described above using anti-myc antibodies.
Density gradient subcellular fractionation was performed by generating lysates as described above using hypotonic lysis buffer and Dounce homogenization. After clearing nuclei and debris by low-speed centrifugation, the supernatant was gently layered onto a discontinuous iodixanol gradient (Opti Prep, Sigma,) from 30 to 2.5% (w/v). Samples were centrifuged at 126 000 g for 30 min at 41C. Fractions were collected from the top of the gradient, and NP40 was added to each fraction to a final concentration of 0.1% for protein solublization. Fractions were then acetone precipitated and incubated overnight at À801C. Precipitates were collected by centrifugation at 13 000 r.p.m. for 15 min in a microcentrifuge, and pellets were dissolved in Laemmli buffer and boiled. The entirety of each sample was then analysed by SDS-PAGE and Western blot to determine the fractionation of DAL-1 and selected DAL-1 mutants using anti-myc antibodies as described above. A Golgi protein marker, anti-membrin (1 : 500; #VAP-PT049, Stressgen Biotechnologies Corp., Victoria, BC, Canada), was used to assess the purity of the membrane fractions.
In vitro and in vivo interaction studies GST-14-3-3Z and GST-bII-spectrin fusion proteins were generated as described previously Yu et al., 2002) . Each fusion protein was freshly isolated for each experiment and verified by SDS-PAGE with Coomassie blue visualization. Protein production was accomplished by the TnT method (Promega, Madison, WI, USA) according to the protocol supplied by the manufacturer. In vitro transcribed and translated proteins were synthesized in the presence of 35 Smethionine and confirmed by SDS-PAGE electrophoresis and autoradiography. In these interaction experiments, radiolabeled proteins were incubated with equimolar amounts of GST-fusion proteins immobilized on glutathione beads overnight at 41C. An aliquot of the unbound fraction was saved and the beads were washed twice with NET buffer (25 mM Tris pH 7.5, 100 mM NaCl, 3 mM EDTA) containing 0.1% Triton X-100 and twice with NET buffer containing 0.05% Triton X-100. The bound and the saved unbound fractions were eluted in Laemmli buffer, boiled 5 min, separated by SDS-PAGE electrophoresis, and analysed by autoradiography. In all experiments, significant binding to immobilized GST alone was not observed. Each interaction experiment has been repeated at least three times with identical results.
To determine CD44 binding, RT4 cells were transfected with 3 mg pcDNA3.myc.DAL-1 or pcDNA3.myc.DU2. After 48 h, cells were lysed in NP40 lysis buffer plus protease inhibitors. An aliquot of the supernatant was saved. Myc beads (Sigma) were added and samples were rotated at 41C overnight, washed, eluted in 2 Â Laemmli sample buffer, loaded on 12% SDS-PAGE gels, and separated by electrophoresis. Bound proteins were identified by Western blot analysis using anti-CD44 antibodies (provided by Dr Larry Sherman, Oregon Health and Science University, Beaverton, OR, USA) as described above.
Microarray analysis
In all, 5 mg of tumor RNA was converted to double-stranded cDNA using a dT-T7 promoter primer. Purified, doublestranded cDNA was then utilized as a template to create biotinylated aRNA. The labeled aRNA target was quantified, fragmented, and 15 mg was utilized for microarray hybridization. The complete target preparation protocol was performed according to the manufacturer's recommendations (Affymetrix, Santa Clara, CA, USA). Labeled targets were hybridized to Affymetrix U133A and U133B GeneChip s microarrays for 16 h and washed following standard protocols. Microarray images were processed using Affymetrix Microarray Analysis Suite (MAS) version 5.0. Each array was scaled so that the average probe set hybridization signal intensity value (target intensity) was 1500. Scaled data for each array was exported to the Siteman Cancer Center Bioinformatics Server (http://bioinformatics.wustl.edu), merged with updated gene annotation data for each probe set on the array, and downloaded for further data visualization and analysis. The completely annotated MIAME-compliant data set can be found at the above noted URL. Basic microarray data visualization, data filtering, and hierarchical clustering were performed using DecisionSite for Functional Genomics (Spotfire). Average fold differences in gene expression between the vector-expressing (lines #3 and #4) and DAL-1-expressing (lines #4 and #10) IOMM-Lee cells were calculated and Student's t-test (uncorrected for multiple comparisons) was used to generate a list of differentially expressed genes between the two groups of IOMM-Lee cell lines.
Quantitative RT-PCR analysis
Oligonucleotide sequences corresponding to the caspase-1, TRL4, and gab1 gene transcripts were designed using Primer Express software (Applied Biosystems, Foster City, CA, USA) and are available on request from the authors. Total cellular RNA (500 ng) from the indicated cell lines was subjected to RT using Omniscript reverse transcriptase (Qiagen, Valencia, CA, USA) and oligo-dT, following the manufacturer's protocol. After first strand synthesis, an equivalent of 50 ng of starting total cellular RNA (1/10th of the cDNA reaction) was added to two duplicate PCR reactions containing 1 Â SybrGreen master mix (Applied Biosystems), 100 nmol/l forward primer, and 100 nmol/l reverse primer in a final volume of 20 ml. Each sample was used in a single reaction that cycled at 951C for 10 min (to activate enzyme), followed by 40 cycles of 951C for 30 s, and 601C for 1 min on an ABI SDS7000 sequence detection system (Applied Biosystems). Fluorescent data were converted into cycle threshold (CT) measurements using the SDS system software and exported to Microsoft Excel. Thermal dissociation plots were examined for biphasic melting curves, indicative of whether primer-dimer formation or other nonspecific product could be contributing to amplification signal.
